Project Grant HT9425261E351
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- Federal Grant Award Summary The University of Washington Office of Sponsored Programs received a $499,551 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026, through June 30, 2028. The project, titled "Enhancing Muscle Stem Cell Targeting to Improve Durability of Genome Editing Therapies for DMD" (Duchenne muscular dystrophy), supports biomedical research addressing Service Member health...
- Federal Grant Award Summary The University of Washington's Office of Sponsored Programs received a $498,600 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2026, through July 31, 2028. The grant supports research investigating anti-dystrophin T cell responses in patients with Duchenne muscular dystrophy (DMD), a progressive genetic muscle disorder affecting the military-relevant population....
- Federal Grant Award Summary The Washington University's Office of Sponsored Research Services received a $894,125 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Understanding and Targeting Epigenetic Vulnerabilities in NF-1-MPNST." The three-year award, effective from July 15, 2025 through July 14, 2028, funds advanced biomedical research investigating epigenetic mechanisms and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of Washington's Office of Sponsored Programs a $1.7M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026, with completion targeted for April 30, 2029. The award supports research and development of low-volume resuscitants for burn treatment in austere conditions under the project title "Radiant Star Low-Volume Resuscitants for Burn Treatment in...
- The University of Washington received a $1.49 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded April 1, 2026, with a completion date of March 31, 2029. The project focuses on developing biomaterial strategies to improve the specificity and efficacy of chimeric antigen receptor (CAR) T cell therapy for breast cancer treatment. This three-year research initiative will be conducted at the University of...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a Project Grant totaling $769,999 under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2026, through July 31, 2029. The award funds research titled "Control of DC Dysfunction Induced by Gamma-Delta Treg Cells for Melanoma Immunotherapy," which addresses dendritic cell (DC) dysfunction mechanisms related to regulatory T cells (Treg) and potential...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a Project Grant of $699,751 under the Military Medical Research and Development program (CFDA 12.420) for a three-year period (May 1, 2026–April 30, 2029). The award funds research titled "Unveiling Mechanisms and Innovative Therapies for ESR1-CCDC170 Fusions in Clinically Aggressive, Endocrine-Resistant and Metastatic Breast Cancers." The project will deliver investigator-initiated biomedical...
- Federal Project Grant Award Summary The University of Washington received a $769,887 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on preventing per- and polyfluoroalkyl substances (PFAS) neurotoxicity through folate pathway intervention. The award was issued on May 15, 2026, with a performance period extending through May 14, 2029. Research activities will be conducted at the University of...
- Federal Grant Award Summary The University of Wisconsin-Madison received a $729,778 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning June 1, 2025 and concluding May 31, 2028. The award supports multiomic analysis of liquid biopsies for biomarker discovery and therapeutic targeting—research aimed at identifying and developing novel diagnostic markers and treatment approaches through comprehensive molecular...